Diarrhea irritable bowel syndrome (IBS-D) was the most common subtype in China, and currently there was no effective cure. Moxibustion plays an important role in the traditional medical systems of China, and it has been promoted for a wide variety of conditions, such as urinary retention, pain, cancer, stroke, constipation, and hypertension. However, most researches of moxibustion on IBS were generally of low quality and the application of moxibustion still lack of high quality evidence. We cond
Conditions
Interventions
Patients in the treatment group were treated by moxibustion therapy once every other day, 3 times a week for 6 weeks in total. Moxa rolls provided by Nanyang Chinese Medicine Airong Co. LTD (Henan, C
Experimental Other
moxibustion therapy
Sponsors
Meiya Xu
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1)met the Rome III diagnostic criteria and Bristol Form Scale for IBS-C; 2)were 18-65 years old; 3) had IBS-D for more than 6 months; 4) had a baseline IBS-Symptom Severity Score (IBS-SSS) of 75 or higher; 5)were with signed informed consent.
Exclusion criteria
Exclusion criteria: 1)were accompanied with inflammatory bowel disease, intestinal organic lesions, peptic ulcer, infectious diarrhea; 2) were accompanied with serious cardiovascular or cerebrovascular diseases, or severe liver or kidney dysfunction; 3) were pregnant or had reproductive plan within 1 month; 4) had participated in other clinical trials 1 month before.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IBS-SSS from week 0 to week 6 6 weeks changes in total IBS-SSS from week 0 to week 6 | — |
Secondary
| Measure | Time frame |
|---|---|
| IBS-SSS from week 6 to week 18 18 weeks changes in total IBS-SSS from week 6 to week 18 | — |
Countries
China
Contacts
Public ContactMeiya Xu
Changshu Hospital Affiliated to Nanjing University of Chinese Medicine
Outcome results
None listed